Normal Appearing White Matter Metabolite Pattern and Sex Differences in Multiple Sclerosis Patients Compared to Healthy Controls

Vasilena Petrova¹, Krasimir Genov²

¹ Clinic of Nerve Diseases, Military Medical Academy, Sofia, Bulgaria
² Clinic of Nerve Diseases, SMHAT, Sofia, Bulgaria

Corresponding author: Vasilena Petrova, Military Medical Academy, Sofia, Bulgaria; Email: petrovadata@gmail.com

Received: 16 Mar 2021 ♦ Accepted: 13 May 2021 ♦ Published: 31 Oct 2022

Citation: Petrova V, Genov K. Normal appearing white matter metabolite pattern and sex differences in multiple sclerosis patients compared to healthy controls. Folia Med (Plovdiv) 2022;64(5):746-753. doi: 10.3897/folmed.64.e66002.

Abstract

Introduction: Proton magnetic resonance spectroscopy (PrMRS) detects changes in brain metabolite levels in vivo.

Aim: The aim of the present study was to evaluate the brain metabolites choline (Cho), creatine (Cr), and N-acetyl aspartate (NAA) in lesion free normal appearing white matter (NAWM) in patients with relapsing-remitting multiple sclerosis (RRMS) versus healthy controls. The second aim was to explore the impact of sex on brain metabolite changes.

Materials and methods: Fifty RRMS patients received PrMRS evaluation of their brain NAWM regions. The results were compared with the findings in 28 healthy demographically matched controls.

Results: We found elevated levels of Cho, Cr, and NAA in NAWM of MS patients in comparison with healthy controls. The NAA/Cr and Cr/NAA ratios were collated. A statistically significant difference between both groups was found only for NAA/Cr and Cr/NAA ratios. It is due to metabolite changes in the female MS patients.

Conclusions: The results of the present study using PrMRS proved metabolic changes in NAWM. Accompanying pathological process should be assumed, preceding plaques of demyelination. The gender impact needs further investigation.

Keywords
disconnection, gender, magnetic resonance spectroscopy

INTRODUCTION

Over the last 25-30 years, magnetic resonance imaging has been accepted as an important and essential method for specifying the multiple sclerosis (MS) diagnosis as well as for monitoring the disease in vivo. Proton magnetic resonance spectroscopy (PrMRS) is a method of investigating brain metabolites and the changes in their concentrations. The PrMRS is the only method specific for injuries of definite cell types.¹ In MS patients, three types of metabolite patterns have been found: of acute and chronic plaques of demyelination, and of normal brain parenchyma (white brain matter outside the zones of demyelination). Studies over the last years have focused on the changes occurring in the brain parenchyma in MS outside the plaques of demyelination. In normal appearing white matter (NAWM) axon damage, without demyelination markers, microglia and astrocyte activation, and inflammation abnormalities
of low intensity are found. MS is an autoimmune disease of genetic predisposition which in combination with factors from the environment, activates a cascade of immune responses and damages the blood-brain barrier. Inflammatory demyelination of the white brain matter of the central nervous system (CNS) occurs with the participation of T and B lymphocytes and macrophages. Conduction of nerve impulses to the CNS is damaged which is clinically manifested as neurologic deficit. The disease affects predominantly young people aged between 30-34 years. Twice as many females are disease-prone compared to males.

**AIM**

The objective of the study was to measure the metabolite markers choline (Cho), creatine (Cr), and N-acetyl aspartate (NAA) in zones of NAWM (brain regions in the white matter without demyelination lesions) using PrMRS. The second goal of the study was to search for sex-determined differences in the parameters studied.

**MATERIALS AND METHODS**

**Proton magnetic resonance spectroscopy**

MRT was performed on MT Signa 1.5T HDxt. The protocol for PrMRS we applied is used at the Department of Diagnostic Imaging of St Ivan Rilski University Multipurpose Hospital for Active Treatment, Sofia. PrMRS is a method in which signals are recorded reflected by the protons of organic molecules – metabolites in CNS. Their concentrations are 1000 times lower than those of water in tissues. The normal brain spectrum is presented by three resonance peaks of the metabolites. The first peak is formed by tetramethyl amines (Cho), which are mainly choline phospholipids. They participate in the synthesis and decomposition of cellular membranes. A second peak is formed by the content of Cr and phosphocreatine. They participate in the energy metabolism. The third peak is of the NAA groups which comprise the NAA localized within the neurons. A fourth peak may be formed, especially in pathologic processes, by lactates and lipids.

For the objective of our study, PrMRS was performed measuring Cho, Cr, and NAA in the zones of subcortical white brain matter free of demyelination lesions. Regions of normal T2 image in the conventional MRI were selected, i.e. zones of NAWM. In the group of healthy controls corresponding zones of testing were selected. The data from the spectroscopes measurement were compared. The frequencies of the metabolites tested were measured in units called parts per million (ppm) and they were graphically presented by peaks of different magnitude for the different metabolites (Fig. 1).

**Figure 1.** PrMRS in an MS patient. T2 image. The NAWM zone of interest is marked, which is free of demyelination lesions, in the right brain hemisphere parietally.

**Patients**

The study included 50 patients with specified MS diagnosis, according to the revised criteria of McDonald. Patients with a history of the disease shorter than 10 years were selected, because of the fact that in 70% of the patients with RRMS the disease progresses to secondary progressive MS within 6-10 years after the onset. The group of the patients studied was compared to a group of 28 healthy individuals, selected according to the corresponding demographic criteria.

**Demographic data**

**Inclusion criteria:**
- patients with clinically proven MS
- age between 20-40 years
- relapsing-remitting type of the disease
- time elapsed since specifying the diagnose up to 10 years
- currently receiving disease-modifying therapy interferon beta-1a
- Expanded Disability Status Scale (EDSS) up to 3.5
- with no evidence of relapse of the disease over the last 2 to 6 months
- with no administration of corticosteroid at least 2 months prior the study

**Exclusion criteria:**
- relapse of the disease over the last 6 months prior to the study
- administration of corticosteroid over the last 2 months prior to the study
• other autoimmune disease
• history of specified diagnosis of depression, severe depressive episodes and/or treatment with antidepressants for symptoms of depression found
• active inflammatory process
• treatment with other type of disease-modifying therapy
• motor deficit, visual or auditory disorders
• alcohol or other psychotropic medications and substances abuse.

Control group:

Inclusion criteria:
• age between 20–40 years
• clinically healthy individuals

Exclusion criteria:
• history of other neurologic disease in the past – epilepsy, insult, encephalitis, meningitis, disorders of the CNS development
• other autoimmune disease
• history of specified diagnosis of depression, severe depressive episodes and/or treatment with antidepressants for symptoms of depression
• active inflammatory process
• alcohol and other psychotropic medications and substances abuse.

All participants signed an informed consent. Demographic data were collected. Neurological examination was performed. PrMRS was performed for both groups. Cho, Cr, and NAA levels were measured in ppm in fronto-parietal NAWM. Corresponding zones of interest were selected in healthy controls. The data obtained were compared.

Statistical analysis

The data obtained with PrMRS were analyzed using the independent samples t-test and the Mann-Whitney test. IBM SPSS statistics v. 23 was used for data processing.[7-12]

RESULTS

We studied 50 patients with clinically definitive RRMS. The distribution by sex was 29 (58%) female and 21 male (42%) MS patients. The individuals tested were 21-40 years old, with a mean age of 33±7 years, and duration of the disease of 4.85±2.68 years. The disease duration from the moment of diagnosis ranged between 5 months and 10 years. The control group counted 28 healthy controls. There were 14 female and 14 male subjects (50% : 50%), aged 27-40 years. The mean age was 33±5 years. All MS patients were employed on a full-time working day. There were 80% full-time employed healthy controls, 6% students and 6% unemployed individuals in the control group. The MS patients were on disease-modifying treatment (mean duration of the treatment of 2.40±2.21 years). They were in a stable condition – remission at least 2 months prior to the tests, (minimal period of since on disease-modifying treatment 3 months, maximum period 8 years and 8 months). EDSS score ranged from 1.0 to 3.5. The distribution by EDSS score was as follows: 1.0 – 16 patients (pts); 1.5 – 10 pts, 2.0 – 11 pts; 2.5 – 11 pts; 3.0 – 0 pts, and 3.5 – 2 pts. Pyramidal functions deterioration was found in 18.5% of the MS patients. Cerebellar system symptoms were found in 8% and sensory symptoms in 7.5% of the patients. There were no abnormal signs with disability for upper limbs. Only 5% had brainstem symptoms and 4.2% had bowel-bladder dysfunction. There were no patients with visual or cerebral function disability included.

All patients and healthy controls underwent conventional MRI and PrMRS. Concentrations of brain metabolites in zones free of demyelination plaques (NAWM) were measured, respectively Cho, Cr, and NAA. Metabolic ratios NAA/Cr, NAA/Cho, Cho/NAA, Cr/NAA, Cho/Cr were registered, respectively. The data of the MRI were analyzed and compared to the data of the control group of healthy individuals in the respective age group (Fig. 2).

The data obtained were indicative of distinct changes in the metabolite concentrations with higher peaks registered in the MS patients.

Higher levels of Cho, Cr, and NAA were found in the MS patients. Statistically significant difference was found only when comparing the mean levels of Cr in healthy (controls) (x=61057±14334.29) and in patients (x=70228±17326.47) with a 5% risk of error. Kolmogorov-Smirnov test was ap-
plied to check the normality of data distribution. The metabolites studied were not normally distributed. We applied the non-parametric Man-Whitney test for comparison (Table 1).

Only the result of the comparison of the mean values of Cr had a p-value ($p=0.025$) lower than the risk of error ($\alpha=0.05$). Therefore, it could be said with 95% probability of certainty that there was a statistically significant difference between the healthy controls and the MS patients regarding the mean levels of this metabolite.

To read the clinical significance of the changes of the brain metabolites found comparative analysis of the changes in the ratios between the metabolites measured was performed, as follows: Cho/Cr, Cho/NAA, Cr/NAA, NAA/Cho, and NAA/Cr. The comparison of the mean values of the NAA/Cr ratio in healthy controls and in MS patients found statistically significant difference respectively in healthy controls ($x=2.59\pm0.46$) and MS patients ($x=2.36\pm0.45$) with a 5% risk of error. In healthy controls, higher levels of the ratio were found.

The comparison of the mean values of the Cr/NAA ratio in healthy controls and MS patients found statistically significant difference respectively in healthy controls ($x=0.40\pm0.08$) and MS patients ($x=0.44\pm0.08$), which was statistically significant with a 5% risk of error. Higher levels of the ratio were found in the MS patients.

When testing the ratios for normal distribution (Kolmogorov-Smirnov test) it turned out that only one ratio was normally distributed (NAA/Cr) and a parametric method of verifying the hypothesis about the difference between the mean values in MS patients and healthy controls was applied (T-test) for it. In all the rest non-parametric test (Mann-Whitney test) was applied to verify the differences (Table 2).

The results of comparison of the NAA/Cr ratio between healthy controls and MS patients had a p-value ($p=0.035$) – smaller than the risk of error ($\alpha=0.05$). Therefore, it could be claimed with a 95% probability of certainty that there was statistically significant difference between healthy controls and MS patients regarding the mean ratio of NAA/Cr metabolites.

The comparison of the Cr/NAA ratio between healthy controls and MS patients had a p-value ($p=0.041$) – smaller than the risk of error ($\alpha=0.05$). Therefore, it could be claimed with a 95% probability of certainty that there was statistically significant difference between healthy controls and MS patients regarding the mean ratio of Cr/NAA metabolites.

### Table 1. Comparative analysis between healthy controls and MS patients for Cho, Cr, and NAA mean values with non-parametric Man-Whitney test

| Metabolite | Group   | N  | Mean     | SD      | p      |
|------------|---------|----|----------|---------|--------|
| Cho        | Group*  | 28 | 78196.43 | 15798.724 | 0.122  |
|            | Group** | 50 | 85682.92 | 20018.070 |        |
| Cr         | Group*  | 28 | 61056.96 | 14334.289 | 0.025  |
|            | Group** | 50 | 70227.98 | 17326.469 |        |
| NAA        | Group*  | 28 | 153609.43 | 23048.165 | 0.151  |
|            | Group** | 50 | 160673.88 | 28647.211 |        |

Cho: choline; Cr: creatine; NAA: N-acetyl aspartate; *: healthy controls; **: MS patients

### Table 2. Comparative analysis between healthy controls and MS patients for Cho, Cr, and NAA mean values with non-parametric Man-Whitney test

| Ratio      | Group   | N  | Mean     | SD      | p      |
|------------|---------|----|----------|---------|--------|
| NAA/Cr     | Group*  | 28 | 2.592    | 0.458   | 0.035  |
|            | Group** | 50 | 2.362    | 0.454   |        |
| Cho/Cr     | Group*  | 28 | 1.332    | 0.384   | 0.567  |
|            | Group** | 50 | 1.280    | 0.417   |        |
| Cho/NAA    | Group*  | 28 | 0.512    | 0.098   | 0.525  |
|            | Group** | 50 | 0.545    | 0.156   |        |
| NAA/Cho    | Group*  | 28 | 2.025    | 0.392   | 0.525  |
|            | Group** | 50 | 1.980    | 0.612   |        |
| Cr/NAA     | Group*  | 28 | 0.398    | 0.076   | 0.041  |
|            | Group** | 50 | 0.439    | 0.083   |        |

*: healthy controls; **: MS patients
There was a change in all the ratios studied in the group of MS patients.

Statistically significant difference was confirmed only for the NAA/Cr and Cr/NAA ratios.

Twice as many females are disease-prone than males. A possible impact of sex on the changes of brain metabolites was studied. The statistical difference assumed between the ratios of the metabolites Cho/Cr, Cho/NAA, Cr/NAA, NAA/Cho, and NAA/Cr studied was analyzed according to sex.

**Males**

The Kolmogorov-Smirnov test for normality of data distribution revealed that only the Cho/Cr ratio was not normally distributed and non-parametric method of testing the hypothesis about the difference between the mean values in MS patients and healthy controls was applied (Mann-Whitney test). In all the rest, parametric test (T-test) was applied to verify the differences (Table 3).

No statistically significant difference was found when comparing the two groups of individuals studied.

**Females**

The difference between the mean values in female healthy controls ($x=2.74\pm0.39$) and female MS patients ($x=2.38\pm0.45$) was statistically significant with a 5% risk of error. In female healthy controls, increased levels of the ratio were found.

The difference between the mean values in female healthy controls ($x=0.44\pm0.08$) and female MS patients ($x=0.37\pm0.06$) was statistically significant with 5% risk of error. In female MS patients, increased levels of the ratio were found.

When testing the ratios of normal distribution (Kolmogorov-Smirnov test), it turned out that NAA/Cr and Cho/Cr were normally distributed. A parametric method of testing the hypothesis about the difference between the mean values in female MS patients and female healthy controls (T-test) was applied for them. In all the rest, non-parametric test (Mann-Whitney test) was applied to verify the differences (Table 4).

The result of the comparison of the NAA/Cr ratio between female healthy controls and female MS pa-

---

**Table 3.** Comparative analysis between male healthy controls and male MS patients for differences in metabolite ratios (Cho/Cr ratio analyzed with Mann-Whitney test, Cho/NAA, NAA/Cho, NAA/Cr, and Cr/NAA with independent samples t-test)

| Ratio     | Group  | N  | Mean | SD   | p   |
|-----------|--------|----|------|------|-----|
| Cho/Cr    | Group* | 14 | 1.264| 0.432| 0.567|
|           | Group**| 21 | 1.291| 0.404|     |
| Cho/NAA   | Group* | 14 | 0.515| 0.115| 0.436|
|           | Group**| 21 | 0.551| 0.146|     |
| NAA/Cho   | Group* | 14 | 2.031| 0.438| 0.453|
|           | Group**| 21 | 1.917| 0.437|     |
| NAA/Cr    | Group* | 14 | 2.447| 0.490| 0.530|
|           | Group**| 21 | 2.343| 0.467|     |
| Cr/NAA    | Group* | 14 | 0.423| 0.083| 0.505|
|           | Group**| 21 | 0.443| 0.086|     |

*: male healthy controls; **: male MS patients

**Table 4.** Comparative analysis between female healthy controls and female MS patients for differences in metabolite ratios (NAA/Cr and Cho/Cr ratios with independent samples t-test, Cho/NAA, NAA/Cho and Cr/NAA with Mann-Whitney test)

| Ratio     | Group  | N  | Mean | SD   | p   |
|-----------|--------|----|------|------|-----|
| NAA/Cr    | Group* | 14 | 2.738| 0.387| 0.014|
|           | Group**| 29 | 2.376| 0.451|     |
| Cho/Cr    | Group* | 14 | 1.400| 0.330| 0.337|
|           | Group**| 29 | 1.272| 0.433|     |
| Cho/NAA   | Group* | 14 | 0.509| 0.082| 0.917|
|           | Group**| 29 | 0.541| 0.165|     |
| NAA/Cho   | Group* | 14 | 2.018| 0.357| 0.917|
|           | Group**| 29 | 2.026| 0.717|     |
| Cr/NAA    | Group* | 14 | 0.378| 0.062| 0.005|
|           | Group**| 29 | 0.436| 0.082|     |

*: female healthy controls; **: female MS patients
patients had a $p=0.014$ $p$-value, smaller than the risk of error ($\alpha=0.05$). Therefore, with a 95% probability of certainty, it could be claimed that there was a statistically significant difference between healthy controls and MS patients regarding the mean ratio of the NAA/Cr metabolites.

The result of the comparison of the Cr/NAA ratio between female healthy controls and female MS patients had a $p=0.005$ $p$-value, smaller than the risk of error ($\alpha=0.05$). Therefore, with a 95% probability of certainty it could be said that there was a statistically significant difference between healthy controls and MS patients regarding the mean ratio of the Cr/NAA metabolites.

The results of the comparison between female healthy controls and female MS patients regarding the rest of the metabolites Cho/Cr, Cho/NAA, and NAA/Cho had a $p$-value greater than the risk of error ($\alpha=0.05$). Therefore, with a 95% probability of certainty, it could be said that there was no statistically significant difference between healthy controls and MS patients regarding their mean ratios.

After verifying the difference between the changes found in the ratios between the brain metabolites and the sex of the individuals, it was found that only in females there was a statistically significant difference in the ratios studied.

Therefore, the female sex factor exerted considerable influence on the changes observed. The role of estrogen in the biosynthetic processes was to be considered.

**DISCUSSION**

Cho is a marker of cellular and membrane turnover. Therefore, an increased level of choline phospholipids is found. The reference about the stages preceding the appearance of a new plaque of demyelination in NAWM reports the increase of the levels of Cho metabolites. The data correspond to the changes found in NAWM in MS patients with PrMRS presented in studies of other research groups. The increased levels of Cho reflect increased activity of Cho metabolism. Cho provides structural integrity and signal function of the cellular membranes. As a phospholipid component (phosphatidylcholine and sphingomyelin), it builds up the cellular membrane. It participates in the formation of the myelin sheath of the nerve fibers. The changes found are in the zones free of demyelination. Regarding the levels of Cr, a difference is found between the two groups again with higher levels of the metabolite tested in the group of the MS patients. Cr is a marker of the energy homeostasis. The data obtained show increased energy exchange, i.e. intensity of the biochemical processes in NAWM in the MS patients tested. Statistically significant differences have been read only for Cr and that for the MS patients. This fact can be interpreted as an increase of the energy utilization in NAWM. The increased energy resources and activity are probably related to a necessity of conducting an electrical signal under the conditions of changed ion homeostasis in the demyelinated axons, and they are also a testimony of active metabolite biosynthetic processes.

The use of PrMRS in our study proved metabolic changes in the regions free of demyelination (NAWM), which suggested the presence of parallel pathologic process prior to the appearance of demyelination plaque. Increased levels of Cho, Cr, and NAA in NAWM in patients with MS were measured. Statistically significant difference when comparing the NAA/Cr and Cr/NAA ratios in female MS patients was found.

**Funding**

The authors have no funding to report.

**Disclosure statement**

The authors declare no actual or potential conflicts of interest.
REFERENCES

1. Milanov I. [Multiple sclerosis and autoimmune demyelinating diseases of the central nervous system.] Sofia: Medicine and physical education; 2014 [Bulgarian].
2. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 32:247–69.
3. [National consensus for diagnosing and treatment of multiple sclerosis.] Sofia, 2018 [Bulgarian].
4. Dwyer MG, Zivadinov R, Tao Y, et al. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurology 2015; 15(1):232.
5. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000; 123:2256–63.
6. O’Keefe J, Nadel L. The hippocampus as a cognitive map. Oxford: Clarendon Press; 1978.
7. Goev V. [Statistical processing and analysis of information from sociological, marketing and political investigations with SPSS]. Stotsanstvo 1996 [Bulgarian].
8. Kaloyanov T, Petrov V. [Statistics] Sofia: UNWE;2014 [Bulgarian].
9. Mishev G, Goev V. [Statistical analysis of time series]. Sofia: Avangard Prima; 2010 [Bulgarian].
10. Pavlova V, Chipeva S. [Statistics.] Sofia: Nova Zvezda; 2012 [Bulgarian].
11. Sepetliev D. [Medical statistics] Sofia, 1976 [In Bulgarian].
12. Chipeva S, Boshnakov V. [Introduction to econometrics]. Sofia: UNWE; 2015 [Bulgarian].
13. Sun J, Song H, Yang Y, et al. Metabolic changes in normal appearing white matter in multiple sclerosis patients using multivoxel magnetic resonance spectroscopy imaging. Medicine 2017; 96(14).
14. Sharma P, Senthilkumar V, Brahmachari V, et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis 2006; 5:1.
15. Shaw GM, Carmichael SL, Yang W, et al. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. Am J Epidemiol 2004; 160:102–9.
16. Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Na1.2 and Na1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA 2004; 101(21):8168–73.
17. Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2017; 88:137–45.
18. Lassmann H, Van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis, FEBS Lett 2011; 585(23): 3715–23.
19. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117:49–58.
20. Fu L, Mattheus PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121:103–13.
21. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical gray and normal appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125(10):2342–52.
22. Molk N, Cohen I, Mangin JF, et al. Visualizing the neural bases of a disconnection syndrome with diffusion tensor imaging. J Cogn Neurosci 2002; 14(4):629–36.
Нормальный вид метаболитов белого вещества и половые различия у пациентов с рассеянным склерозом по сравнению со здоровыми пациентами контрольной группы

Василена Петрова¹, Красимир Генов²

¹ Клиника нервных болезней, Военно-медицинскная академия, София, Болгария
² Клиника нервных болезней, Вторая МБАЛ, София, Болгария

Адрес для корреспонденции: Василена Петрова, Клиника нервных болезней, Военно-медицинская академия, София, Болгария; Email: petrovadata@gmail.com

Дата получения: 16 марта 2021 • Дата приемки: 13 мая 2021 • Дата публикации: 31 октября 2022

Образец цитирования: Petrova V, Genov K. Normal appearing white matter metabolite pattern and sex differences in multiple sclerosis patients compared to healthy controls. Folia Med (Plovdiv) 2022;64(5):746-753. doi: 10.3897/folmed.64.e66002.

Резюме

Введение: Протонная магнитно-резонансная спектроскопия (PrMRS) выявляет изменения уровня метаболитов в головном мозге in vivo.

Цель: Целью настоящего исследования было оценить метаболиты головного мозга холина (Cho), креатина (Cr) и N-ацетиласпартата (NAA) в нормально выглядящем белом веществе без поражений (NAWM) у пациентов с рецидивирующим-ремиттирующим рассеянным склерозом (RRMS) по сравнению со здоровыми пациентами контрольной группы. Вторая цель заключалась в изучении влияния пола на изменения метаболитов в головном мозге.

Материалы и методы: Пятьдесят пациентов с RRMS получили оценку PrMRS областей NAWM головного мозга. Результаты сравнивали с результатами 28 здоровых демографически сопоставимых пациентов контрольных групп.

Результаты: Мы обнаружили повышенные уровни Cho, Cr и NAA в NAWM у пациентов с рассеянным склерозом по сравнению со здоровыми пациентами контрольной группы. Соотношения NAA/Cr и Cr/NAA сопоставляли. Статистически значимая разница между обеими группами была обнаружена только для соотношений NAA/Cr и Cr/NAA. Это связано с изменениями метаболитов у больных женского пола с рассеянным склерозом.

Заключение: Результаты настоящего исследования с использованием PrMRS подтвердили метаболические изменения при NAWM. Следует предполагать сопутствующий патологический процесс, предшествующий развитию бляшек демиелинизации. Гендерное воздействие требует дальнейшего изучения.

Ключевые слова

разъединение, пол, магнитно-резонансная спектроскопия